Petrovax Pharm President Elena Arkhangelskaya delivered an expert speech at the 3rd Annual Conference «The pharma business in Russia: development strategies in times of change» held on September 23 at Marriott Royal Aurora Moscow.

On an interactive basis, the conference participants discussed major market trends in 2015 and development prospects, continuation of the legal reform in healthcare and pharma, import substitution specifics in Russia, and investment attractiveness of the Russian pharma market. The focus was also on the VED price regulation, legislation unification within the framework of the Customs Union and the EAEU, and drug registration.

Speaking at the health legislation session, Elena Arkhangelskaya shared experience from a pharmaceutical manufacturer perspective in respect of the opportunities and difficulties associated with large-scale implementation of new legislative initiatives. She also spoke about a successfully implemented «deep» localization project concerning high-tech immunobiologicals. In August 2015, the Russian Ministry of Health issued an authorization for Petrovax Pharm for a  full-cycle manufacturing of  13-valent conjugated pneumococcal vaccine Prevenar® 13 including all production stages, i.e. preparation of a finished dosage form (formulation), primary packaging (filling into disposable syringes), secondary packaging, and release quality control.

Back to the list

© Petrovax
The materials posted on the site are for informational purposes only and are not intended to advertise or promote the manufacturer or medications produced.